Compare · AZN vs DYN
AZN vs DYN
Side-by-side comparison of AstraZeneca PLC (AZN) and Dyne Therapeutics Inc. (DYN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and DYN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $263.10B, about 53.5x DYN ($4.92B).
- Over the past year, AZN is down 11.7% and DYN is up 93.6% - DYN leads by 105.3 points.
- DYN has been more active in the news (16 items in the past 4 weeks vs 15 for AZN).
- AZN has more recent analyst coverage (25 ratings vs 22 for DYN).
- Company
- AstraZeneca PLC
- Dyne Therapeutics Inc.
- Price
- $166.23-2.02%
- $25.90-1.71%
- Market cap
- $263.10B
- $4.92B
- 1M return
- -3.66%
- +0.10%
- 1Y return
- -11.71%
- +93.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2020
- News (4w)
- 15
- 16
- Recent ratings
- 25
- 22
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Dyne Therapeutics Inc.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.
Latest AZN
- A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
- TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
Latest DYN
- Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Rhodes Jason P sold $65,184,894 worth of shares (2,586,928 units at $25.20) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Commercial Officer Friedl-Naderer Johanna sold $5,939 worth of shares (226 units at $26.28) as part of a pre-agreed trading plan, decreasing direct ownership by 0.15% to 153,982 units (SEC Form 4) to satisfy withholding tax
- Chief Medical Officer Kerr Douglas sold $40,892 worth of shares (1,556 units at $26.28) as part of a pre-agreed trading plan, decreasing direct ownership by 0.92% to 167,599 units (SEC Form 4) to satisfy withholding tax
- CEO & President Cox John sold $131,032 worth of shares (4,986 units at $26.28) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 363,165 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Lucera Erick sold $47,225 worth of shares (1,797 units at $26.28) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 119,766 units (SEC Form 4) to satisfy withholding obligation
- SEC Form 144 filed by Dyne Therapeutics Inc.
- SEC Form 144 filed by Dyne Therapeutics Inc.
- SEC Form 144 filed by Dyne Therapeutics Inc.
- SEC Form 144 filed by Dyne Therapeutics Inc.